People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Hims & Hers Health stock down 3% as analyst predicts Q4 revenue could miss estimates amid decelerating growth in weight-loss ...

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...